# DFine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dfine

- Industry: Medical Devices & Equipment
- Headquarters: San Jose, US
- Website: www.dfineinc.com
- Total disclosed funding: $117M
- Latest round: Series E (Jul 7, 2010)
- Investors on record: 7

## About

DFine Inc. develops advanced medical technologies focused on spine treatment, specializing in minimally invasive procedures that enhance patient care and outcomes.Founded in 2004, DFine Inc. is based in San Jose, California, US, and specializes in innovative solutions for spinal interventions. The company produced significant advancements in vertebral augmentation technologies. DFine has successfully completed 7 deals, with its most recent deal occurring on November 8, 2011, when it raised USD 25 mn from a group of investors including Apothecary Capital, NexPoint Asset Management, and others. The company was established to fill a niche in spine treatment, reflecting a commitment to improving surgical outcomes for patients.DFine Inc. specializes in advanced medical technologies for spine treatment, particularly focusing on minimally invasive procedures that address pathologies of the vertebrae. Their core offerings include steerable balloon-assisted vertebral augmentation systems, such as the Arcadia™ Next Generation Balloon Catheter and the StabiliT® MX Vertebral Augmentation System. These products are designed to create targeted, controlled cavities for the injection of high-viscosity cement, which serves as an internal cast to stabilize fractured vertebrae and provide pain relief. Additional offerings include the STAR™ Tumor Ablation System, which employs targeted radiofrequency ablation for treating metastatic spinal tumors. DFine's products are utilized predominantly in hospitals and surgical centers across North America, Europe, and select markets in Asia, serving orthopedic and spinal surgeons.DFine Inc. generates revenue through direct sales of its medical devices and procedural solutions to healthcare facilities, including hospitals and outpatient surgical centers. Transactions typically occur on a B2B basis, where clients purchase products based on their inventory needs for specific procedures. The company's flagship products, including the StabiliT® Vertebral Augmentation System, are sold through established pricing plans based on individual product configurations and usage requirements, supported by training and educational resources that ensure effective implementation in clinical settings.DFine Inc. plans to leverage the USD 25 mn raised in November 2011 to further develop its product offerings and enhance market presence. The company is focused on launching new products aimed at improving surgical outcomes in the spinal treatment sector, with a roadmap for releases in upcoming years as R&D progresses. Additionally, DFine is exploring expansion into emerging markets in Asia and Europe, targeting specific areas for growth by 2015. Recent funding will support these initiatives by enabling the development of innovative solutions and bolstering marketing efforts to capture new clientele.

## Funding rounds

- Series E, Jul 7, 2010, $36M — OrbiMed Advisors, Prospect Venture Partners, Vanguard Ventures, Split Rock Partners, NexPoint Asset Management, Apothecary Capital
- Series D, Jan 2, 2009, $35M — Prospect Venture Partners, Vanguard Ventures, BBT Capital Management
- Series D, Oct 6, 2008, $30M — Prospect Venture Partners, Vanguard Ventures, NexPoint Asset Management, Apothecary Capital
- Series C, Feb 9, 2007, $9.4M — Prospect Venture Partners, Vanguard Ventures
- Series B, Dec 8, 2005, $6.5M — Prospect Venture Partners

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B, Series C, Series D, Series E
- Vanguard Ventures (https://capitalatlas.ai/funds/vanguard-ventures) — Series C, Series D, Series E
- NexPoint Asset Management (https://capitalatlas.ai/funds/nexpoint-asset-management) — Series D, Series E
- Apothecary Capital — Series D, Series E
- BBT Capital Management — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E
- Split Rock Partners (https://capitalatlas.ai/funds/split-rock-partners) — Series E